{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:27:41Z","timestamp":1778614061878,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T00:00:00Z","timestamp":1542240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T00:00:00Z","timestamp":1542240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2019,2,13]]},"DOI":"10.1007\/s40257-018-0402-5","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T03:47:02Z","timestamp":1542253622000},"page":"115-122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Antibody-Based Therapies for Cutaneous T-Cell Lymphoma"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6587-2032","authenticated-orcid":false,"given":"Macartney","family":"Welborn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8971-4565","authenticated-orcid":false,"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,15]]},"reference":[{"issue":"7","key":"402_CR1","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1001\/archderm.143.7.854","volume":"143","author":"VD Criscione","year":"2007","unstructured":"Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973\u20132002. Arch Dermatol. 2007;143(7):854\u20139.","journal-title":"Arch Dermatol"},{"issue":"5","key":"402_CR2","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1309\/AJCPH2PHXFCX3BOX","volume":"141","author":"RT Vollmer","year":"2014","unstructured":"Vollmer RT. A review of survival in mycosis fungoides. Am J Clin Pathol. 2014;141(5):706\u201311.","journal-title":"Am J Clin Pathol"},{"issue":"31","key":"402_CR3","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","volume":"28","author":"NS Agar","year":"2010","unstructured":"Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730\u20139.","journal-title":"J Clin Oncol"},{"issue":"32","key":"402_CR4","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","volume":"33","author":"JJ Scarisbrick","year":"2015","unstructured":"Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33(32):3766\u201373.","journal-title":"J Clin Oncol"},{"issue":"18","key":"402_CR5","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","volume":"18","author":"R Talpur","year":"2012","unstructured":"Talpur R, Singh L, Daulat S, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18(18):5051\u201360.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"402_CR6","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","volume":"28","author":"M Duvic","year":"2010","unstructured":"Duvic M, Donato M, Dabaja B, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and S\u00e9zary syndrome. J Clin Oncol. 2010;28(14):2365\u201372.","journal-title":"J Clin Oncol"},{"issue":"4","key":"402_CR7","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"JA Francisco","year":"2003","unstructured":"Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458\u201365.","journal-title":"Blood"},{"issue":"4","key":"402_CR8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/mabs.20230","volume":"4","author":"NW Van de Donk","year":"2012","unstructured":"Van de Donk NW, Dhimolea E. Brentuximab vedotin. MAbs. 2012;4(4):458\u201365.","journal-title":"MAbs."},{"issue":"1","key":"402_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1600-065X.2011.01057.x","volume":"244","author":"DR Withers","year":"2011","unstructured":"Withers DR, Gaspal FM, Bekiaris V, et al. OX40 and CD30 signals in CD4(+) T-cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4(+) T-cell memory but not effector function. Immunol Rev. 2011;244(1):134\u201348.","journal-title":"Immunol Rev"},{"issue":"32","key":"402_CR10","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","volume":"33","author":"M Duvic","year":"2015","unstructured":"Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-Cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759\u201365.","journal-title":"J Clin Oncol"},{"issue":"32","key":"402_CR11","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","volume":"33","author":"YH Kim","year":"2015","unstructured":"Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of Brentuximab vedotin in mycosis fungoides and s\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750\u20138.","journal-title":"J Clin Oncol"},{"issue":"10094","key":"402_CR12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"Prince HM, Kim YH, Horwitz SM, ALCANZA Study Group, et al. Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555\u201366.","journal-title":"Lancet."},{"issue":"19","key":"402_CR13","doi-asserted-by":"publisher","first-page":"6217","DOI":"10.1158\/1078-0432.CCR-09-0162","volume":"15","author":"M Duvic","year":"2009","unstructured":"Duvic M, Reddy SA, Pinter-brown L, et al. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res. 2009;15(19):6217\u201324.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"402_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","volume":"146","author":"A Forero-torres","year":"2009","unstructured":"Forero-torres A, Leonard JP, Younes A, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146(2):171\u20139.","journal-title":"Br J Haematol"},{"issue":"1","key":"402_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4049\/jimmunol.166.1.103","volume":"166","author":"DP Andrew","year":"2001","unstructured":"Andrew DP, Ruffing N, Kim CH, et al. C-C chemokine receptor 4 expression defines a major subset of circulating nonintestinal memory T cells of both Th1 and Th2 potential. J Immunol. 2001;166(1):103\u201311.","journal-title":"J Immunol."},{"issue":"1","key":"402_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1067\/mjd.2003.132","volume":"48","author":"T Kakinuma","year":"2003","unstructured":"Kakinuma T, Sugaya M, Nakamura K, et al. Thymus and activation-regulated chemokine (TARC\/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol. 2003;48(1):23\u201330.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"402_CR17","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-03-2068","volume":"64","author":"R Niwa","year":"2004","unstructured":"Niwa R, Shoji-hosaka E, Sakurada M, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 2004;64(6):2127\u201333.","journal-title":"Cancer Res"},{"issue":"8","key":"402_CR18","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00262-008-0632-0","volume":"58","author":"A Ito","year":"2009","unstructured":"Ito A, Ishida T, Yano H, et al. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD\/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol Immunother. 2009;58(8):1195\u2013206.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"402_CR19","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","volume":"125","author":"M Duvic","year":"2015","unstructured":"Duvic M, Pinter-brown LC, Foss FM, et al. Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883\u20139.","journal-title":"Blood"},{"issue":"11","key":"402_CR20","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","volume":"32","author":"M Ogura","year":"2014","unstructured":"Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157\u201363.","journal-title":"J Clin Oncol"},{"key":"402_CR21","unstructured":"Kim et al. Anti-CCR4 Monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL): results from the Phase III MAVORIC Study. Blood. 2017;130(Suppl 1):817. Accessed 31 July 2018."},{"issue":"6","key":"402_CR22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamadermatol.2018.0884","volume":"154","author":"J Dai","year":"2018","unstructured":"Dai J, Almazan TH, Hong EK, et al. Potential association of anti-CCR4 antibody mogamulizumab and graft-vs-host disease in patients with mycosis fungoides and S\u00e9zary syndrome. JAMA Dermatol. 2018;154(6):728\u201330.","journal-title":"JAMA Dermatol."},{"key":"402_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","volume":"77","author":"F Trautinger","year":"2017","unstructured":"Trautinger F, Eder J, Assaf C, et al. European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014update 2017. Eur J Cancer. 2017;77:57\u201374.","journal-title":"Eur J Cancer"},{"issue":"8625","key":"402_CR24","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/S0140-6736(88)90588-0","volume":"2","author":"G Hale","year":"1988","unstructured":"Hale G, Dyer MJ, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet. 1988;2(8625):1394\u20139.","journal-title":"Lancet"},{"issue":"2","key":"402_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","volume":"22","author":"L Ginaldi","year":"1998","unstructured":"Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res. 1998;22(2):185\u201391.","journal-title":"Leuk Res."},{"issue":"17","key":"402_CR26","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","volume":"359","author":"AJ Coles","year":"2008","unstructured":"Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786\u2013801.","journal-title":"N Engl J Med."},{"issue":"11","key":"402_CR27","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","volume":"101","author":"J Lundin","year":"2003","unstructured":"Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/S\u00e9zary syndrome. Blood. 2003;101(11):4267\u201372.","journal-title":"Blood"},{"issue":"12","key":"402_CR28","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3109\/10428190903216770","volume":"50","author":"C Querfeld","year":"2009","unstructured":"Querfeld C, Mehta N, Rosen ST, et al. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma. 2009;50(12):1969\u201376.","journal-title":"Leuk Lymphoma."},{"issue":"3","key":"402_CR29","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/bjd.12690","volume":"170","author":"A De Masson","year":"2014","unstructured":"De Masson A, Guitera P, Brice P, et al. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol. 2014;170(3):720\u20134.","journal-title":"Br J Dermatol."},{"key":"402_CR30","first-page":"702","volume":"90","author":"PL Zinzani","year":"2005","unstructured":"Zinzani PL, Alinari L, Tani M, et al. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica. 2005;90:702\u20133.","journal-title":"Haematologica"},{"issue":"6","key":"402_CR31","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3324\/haematol.11127","volume":"92","author":"MG Bernengo","year":"2007","unstructured":"Bernengo MG, Quaglino P, Comessatti A, et al. Low-dose intermittent alemtuzumab in the treatment of S\u00e9zary syndrome: clinical and immunologic findings in 14 patients. Haematologica. 2007;92(6):784\u201394.","journal-title":"Haematologica"},{"issue":"117","key":"402_CR32","doi-asserted-by":"publisher","first-page":"117ra7","DOI":"10.1126\/scitranslmed.3003008","volume":"4","author":"RA Clark","year":"2012","unstructured":"Clark RA, Watanabe R, Teague JE, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med. 2012;4(117):117ra7.","journal-title":"Sci Transl Med."},{"issue":"1","key":"402_CR33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/DAD.0000000000000156","volume":"37","author":"MJ Nevet","year":"2015","unstructured":"Nevet MJ, Zuckerman T, Sahar D, Bergman R. Transformation of S\u00e9zary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity. Am J Dermatopathol. 2015;37(1):73\u20137.","journal-title":"Am J Dermatopathol"},{"key":"402_CR34","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"402_CR35","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/DAD.0b013e31821c35cb","volume":"34","author":"K Kantekure","year":"2012","unstructured":"Kantekure K, Yang Y, Raghunath P, et al. Expression patterns of the immunosuppressive proteins PD-1\/CD279 and PD-L1\/CD274 at different stages of cutaneous T-cell lymphoma\/mycosis fungoides. Am J Dermatopathol. 2012;34(1):126\u20138.","journal-title":"Am J Dermatopathol"},{"issue":"23","key":"402_CR36","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698\u2013704.","journal-title":"J Clin Oncol"},{"issue":"22","key":"402_CR37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V128.22.181.181","volume":"128","author":"M Khodadoust","year":"2016","unstructured":"Khodadoust M, Rook AH, Porcu P, Foss FM, Moskowitz AJ, Shustov AR, et al. Pembrolizumab for treatment of relapsed\/refractory mycosis fungoides and S\u00e9zary syndrome: clinical efficacy in a CITN multicenter phase 2 study. Blood. 2016;128(22):181.","journal-title":"Blood"},{"key":"402_CR38","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood.V72.5.1805.1805","volume":"72","author":"TA Waldmann","year":"1988","unstructured":"Waldmann TA, Goldman CK, Bongiovanni KF, et al. Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with antiTac, a monoclonal antibody to the receptor for interleukin-2. Blood. 1988;72:1805\u201316.","journal-title":"Blood"},{"key":"402_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/CMAR.S5009","volume":"2","author":"F Lansigan","year":"2010","unstructured":"Lansigan F, Stearns DM, Foss F. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Manag Res. 2010;2:53\u20139.","journal-title":"Cancer Manag Res."},{"issue":"11","key":"402_CR40","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","volume":"28","author":"HM Prince","year":"2010","unstructured":"Prince HM, Duvic M, Martin A, et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(11):1870\u20137.","journal-title":"J Clin Oncol"},{"issue":"11","key":"402_CR41","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1182\/blood-2006-12-062877","volume":"109","author":"YH Kim","year":"2007","unstructured":"Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007;109(11):4655\u201362.","journal-title":"Blood"},{"key":"402_CR42","doi-asserted-by":"crossref","unstructured":"Deirdre\u00a0O\u2019Mahony\u00a0et al. Phase I trial of siplizumab in CD2-positive lymphoproliferative disease. Blood. 2005;106(11):3353. http:\/\/www.bloodjournal.org\/content\/106\/11\/3353. Accessed 31 July 2018.","DOI":"10.1182\/blood.V106.11.3353.3353"},{"key":"402_CR43","doi-asserted-by":"crossref","unstructured":"Deirdre O\u2019Mahony et al. EBV-related lymphoproliferative disease complicating therapy with siplizumab, a novel anti-CD2 mediated T- and NK-cell depleting agent, in patients with T-cell malignancies. Blood. 2007;110(11):3565. http:\/\/www.bloodjournal.org\/content\/110\/11\/3565. Accessed 31 July 2018.","DOI":"10.1182\/blood.V110.11.3565.3565"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-018-0402-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0402-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0402-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T13:53:27Z","timestamp":1659102807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-018-0402-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,15]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2,13]]}},"alternative-id":["402"],"URL":"https:\/\/doi.org\/10.1007\/s40257-018-0402-5","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,15]]},"assertion":[{"value":"15 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Madeleine Duvic is science and advisory committee member for Millennium Pharmaceuticals, consulting and science advisor for Kyowa Pharmaceuticals, and on the advisory board for Seattle Genetics. Macartney Welborn has no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}